David T. Nash

2.4k total citations
69 papers, 1.7k citations indexed

About

David T. Nash is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, David T. Nash has authored 69 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Surgery, 25 papers in Cardiology and Cardiovascular Medicine and 13 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in David T. Nash's work include Lipoproteins and Cardiovascular Health (22 papers), Blood Pressure and Hypertension Studies (11 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (9 papers). David T. Nash is often cited by papers focused on Lipoproteins and Cardiovascular Health (22 papers), Blood Pressure and Hypertension Studies (11 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (9 papers). David T. Nash collaborates with scholars based in United States, Canada and Australia. David T. Nash's co-authors include Michael D. Petraglia, Howard Fillit, Stephen D. Nash, Andrea Zuckerman, Tatjana Rundek, Eugene Braunwald, Frank M. Sacks, Lemuel A. Moyé, Marc A. Pfeffer and Jean L. Rouleau and has published in prestigious journals such as The Lancet, JAMA and Circulation.

In The Last Decade

David T. Nash

65 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David T. Nash United States 22 751 464 391 180 159 69 1.7k
J. C. M. Witteman Netherlands 12 568 0.8× 568 1.2× 324 0.8× 190 1.1× 96 0.6× 17 1.6k
Virginia Fitzpatrick United States 9 1.5k 1.9× 794 1.7× 883 2.3× 178 1.0× 176 1.1× 9 2.4k
Michael Messig United States 23 831 1.1× 536 1.2× 629 1.6× 266 1.5× 156 1.0× 43 2.0k
Mary M. Kimberly United States 14 533 0.7× 274 0.6× 529 1.4× 93 0.5× 165 1.0× 22 1.3k
Evangelos C. Rizos Greece 23 575 0.8× 415 0.9× 611 1.6× 95 0.5× 396 2.5× 77 2.2k
Sreenivasa Rao Kondapally Seshasai United Kingdom 12 588 0.8× 691 1.5× 1.0k 2.7× 137 0.8× 366 2.3× 21 2.2k
Thomas F. Whayne United States 20 385 0.5× 331 0.7× 297 0.8× 42 0.2× 267 1.7× 82 1.3k
Ramón Corbalán Chile 26 647 0.9× 1.7k 3.7× 428 1.1× 162 0.9× 301 1.9× 114 2.6k
Peter C.Y. Tong Hong Kong 25 312 0.4× 314 0.7× 847 2.2× 66 0.4× 302 1.9× 38 2.0k

Countries citing papers authored by David T. Nash

Since Specialization
Citations

This map shows the geographic impact of David T. Nash's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David T. Nash with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David T. Nash more than expected).

Fields of papers citing papers by David T. Nash

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David T. Nash. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David T. Nash. The network helps show where David T. Nash may publish in the future.

Co-authorship network of co-authors of David T. Nash

This figure shows the co-authorship network connecting the top 25 collaborators of David T. Nash. A scholar is included among the top collaborators of David T. Nash based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David T. Nash. David T. Nash is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nash, David T.. (2024). Systolic Hypertension. PubMed. 61(12). 962–962. 1 indexed citations
2.
Bhagirath, Vinai, David T. Nash, Darryl Wan, & Sonia S. Anand. (2022). Building Your Peripheral Artery Disease Toolkit: Medical Management of Peripheral Artery Disease in 2022. Canadian Journal of Cardiology. 38(5). 634–644. 7 indexed citations
3.
Taplin, Mary‐Ellen, Arif Hussain, Satish Shah, et al.. (2019). ProSTAR: A phase Ib/II study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 37(7_suppl). TPS335–TPS335. 12 indexed citations
4.
Henderson, Peter W., et al.. (2015). Objective Comparison of Commercially Available Breast Implant Devices. Aesthetic Plastic Surgery. 39(5). 724–732. 24 indexed citations
5.
Nash, David T., et al.. (2014). Ocular surface diseases and corneal refractive surgery. Current Opinion in Ophthalmology. 25(4). 264–269. 28 indexed citations
6.
Nash, David T. & Stephen D. Nash. (2008). Ranolazine for chronic stable angina. The Lancet. 372(9646). 1335–1341. 57 indexed citations
7.
Nash, David T.. (2008). Use of Vascular Ultrasound in Clinical Trials to Evaluate New Cardiovascular Therapies. Journal of the National Medical Association. 100(2). 222–229. 4 indexed citations
8.
Fillit, Howard, David T. Nash, Tatjana Rundek, & Andrea Zuckerman. (2008). Cardiovascular risk factors and dementia. ˜The œAmerican journal of geriatric pharmacotherapy. 6(2). 100–118. 173 indexed citations
9.
Nash, David T.. (2007). Rationale for Combination Therapy in Hypertension Management: Focus on Angiotensin Receptor Blockers and Thiazide Diuretics. Southern Medical Journal. 100(4). 386–392. 11 indexed citations
10.
Nash, David T.. (2007). Nutritional and exercise aspects of cognitive impairment. Journal of clinical lipidology. 1(4). 242–247. 7 indexed citations
11.
Nash, David T.. (2004). A statin for a patient with hyperlipidemia and hepatitis C?. Postgraduate Medicine. 115(5). 86–86. 2 indexed citations
12.
Nash, David T.. (2004). Cardiovascular risk beyond LDL-C levels. Postgraduate Medicine. 116(3). 11–15. 17 indexed citations
13.
Nash, David T.. (2003). Outcomes of Medical vs Invasive Therapy for Elderly Patients With Angina. JAMA. 289(21). 2794–2794. 1 indexed citations
14.
Nash, David T.. (1996). Meeting National Cholesterol Education Goals in Clinical Practice—A Comparison of Lovastatin and Fluvastatin in Primary Prevention. The American Journal of Cardiology. 78(6). 26–31. 15 indexed citations
15.
Sacks, Frank M., Jean-Lucien Rouleau, Lemuel A. Moyé, et al.. (1995). Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levels. The American Journal of Cardiology. 75(8). 621–623. 33 indexed citations
16.
Bradford, Reagan H., Charles L. Shear, Carlos A. Dujovne, et al.. (1994). Expanded clinical evaluation of lovastatin (EXCEL) study results: Two-year efficacy and safety follow-up. The American Journal of Cardiology. 74(7). 667–673. 88 indexed citations
17.
Mehta, Jawahar L., Larry M. Lopez, N. D. Vlachakis, et al.. (1993). Double-blind evaluation of the dose-response relationship of amlodipine in essential hypertension. American Heart Journal. 125(6). 1704–1710. 23 indexed citations
18.
Dujovne, Carlos A., A.N. Chremos, James L. Pool, et al.. (1991). Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin. The American Journal of Medicine. 91(1). S25–S30. 91 indexed citations
19.
Nash, David T.. (1990). Alpha‐adrenergic blockers: Mechanism of action, blood pressure control, and effects on lipoprotein metabolism. Clinical Cardiology. 13(11). 764–772. 46 indexed citations
20.
Nash, David T., et al.. (1977). The Erysichthon syndrome. Progression of coronary atherosclerosis and dietary hyperlipidemia.. Circulation. 56(3). 363–365. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J. C. M. Witteman Breakdown of academic impact, for papers by Virginia Fitzpatrick Breakdown of academic impact, for papers by Michael Messig Breakdown of academic impact, for papers by Mary M. Kimberly Breakdown of academic impact, for papers by Evangelos C. Rizos Breakdown of academic impact, for papers by Sreenivasa Rao Kondapally Seshasai Breakdown of academic impact, for papers by Thomas F. Whayne Breakdown of academic impact, for papers by Ramón Corbalán Breakdown of academic impact, for papers by Peter C.Y. Tong
Rankless by CCL
2026